Based on our experience so far, our approach is especially effective in rapidly screening suspected variations in LDLR/PCSK9 among patients displaying obvious FH phenotypes or with a family history of the condition rather than for large-scale population screening. The gene discussed is LDLR; the disease is familial hyperaldosteronism.